Cipla Limited FDA-483
FDA has released the FDA-483 issued following a 9/24-9/28 inspection at Cipla Limited, a Goa, India, drug manufacturer. The two inspection observations were:
- batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in manufacturing; and
- written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up.